Investors sold shares of Pfizer, Inc. (NYSE:PFE) on strength during trading hours on Tuesday. $72.31 million flowed into the stock on the tick-up and $99.79 million flowed out of the stock on the tick-down, for a money net flow of $27.48 million out of the stock. Of all stocks tracked, Pfizer had the 0th highest net out-flow for the day. Pfizer traded up $0.22 for the day and closed at $36.20

Several equities research analysts have issued reports on the stock. Barclays PLC set a $38.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, October 11th. Jefferies Group LLC set a $38.00 price target on shares of Pfizer and gave the company a “neutral” rating in a report on Monday. Berenberg Bank reissued a “hold” rating and issued a $36.00 price target (down previously from $39.00) on shares of Pfizer in a report on Tuesday, August 15th. BMO Capital Markets set a $37.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, October 10th. Finally, Deutsche Bank AG set a $38.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, October 11th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $38.15.

The stock has a 50-day moving average of $35.41 and a 200 day moving average of $33.80. The company has a market cap of $213.09 billion, a price-to-earnings ratio of 26.21 and a beta of 1.00.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The company had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter last year, the business earned $0.64 earnings per share. Pfizer’s revenue was down 1.9% on a year-over-year basis. Analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 3.57%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s dividend payout ratio is presently 94.12%.

In other Pfizer news, insider Alexander R. Mackenzie sold 7,350 shares of Pfizer stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $34.00, for a total value of $249,900.00. Following the transaction, the insider now owns 124,774 shares in the company, valued at $4,242,316. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Sally Susman sold 38,230 shares of Pfizer stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the transaction, the insider now owns 145,649 shares in the company, valued at approximately $5,097,715. The disclosure for this sale can be found here. In the last quarter, insiders sold 464,521 shares of company stock worth $15,813,961. Company insiders own 0.06% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the business. First National Bank of Mount Dora Trust Investment Services grew its position in Pfizer by 9.4% in the third quarter. First National Bank of Mount Dora Trust Investment Services now owns 136,863 shares of the biopharmaceutical company’s stock valued at $4,886,000 after acquiring an additional 11,798 shares during the last quarter. Beacon Financial Group grew its position in Pfizer by 33.9% in the third quarter. Beacon Financial Group now owns 305,375 shares of the biopharmaceutical company’s stock valued at $10,902,000 after acquiring an additional 77,305 shares during the last quarter. McQueen Ball & Associates Inc. grew its position in Pfizer by 4.7% in the third quarter. McQueen Ball & Associates Inc. now owns 60,602 shares of the biopharmaceutical company’s stock valued at $2,163,000 after acquiring an additional 2,724 shares during the last quarter. Eqis Capital Management Inc. grew its position in Pfizer by 69.9% in the third quarter. Eqis Capital Management Inc. now owns 63,349 shares of the biopharmaceutical company’s stock valued at $2,262,000 after acquiring an additional 26,064 shares during the last quarter. Finally, Curbstone Financial Management Corp grew its position in Pfizer by 108.5% in the third quarter. Curbstone Financial Management Corp now owns 58,403 shares of the biopharmaceutical company’s stock valued at $2,085,000 after acquiring an additional 30,398 shares during the last quarter. Hedge funds and other institutional investors own 68.98% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://theolympiareport.com/2017/10/19/traders-sell-pfizer-inc-pfe-on-strength-pfe-2.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.